James New
Directeur Général chez Wavodyne Therapeutics, Inc.
Profil
James New founded Wavodyne Therapeutics, Inc., where he worked as Chairman & Chief Executive Officer.
Dr. New also formerly worked at Abrika Pharmaceuticals LLP, as Chief Executive Officer, Veloxis Pharmaceuticals A, as President & Chief Executive Officer, AIKO Biotechnology, Inc., as Chief Executive Officer, Synaptogenix, Inc., as President & Chief Executive Officer in 2014, Neurotrope, Inc., as Director in 2014, Bristol Myers Squibb Co., as Principal, Pfizer Inc., as Principal, Novartis AG, as Principal, and GSK Plc, as Principal.
Dr. New received his undergraduate degree from State University of New York College at Geneseo, doctorate degree from State University of New York at Buffalo, graduate degree from the University of Maine, and Masters Business Admin degree from Columbia Business School.
Postes actifs de James New
| Sociétés | Poste | Début |
|---|---|---|
Wavodyne Therapeutics, Inc.
 Wavodyne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Wavodyne Therapeutics, Inc. develops and commercializes novel small molecule therapeutics for the treatment of memory and cognitive disorders resulting from neuro-inflammatory processes. The firm also provides research and development services. The company was founded by Jim New and is headquartered in Rochester, NY. | Directeur Général | - |
Anciens postes connus de James New
| Sociétés | Poste | Fin |
|---|---|---|
| NEUROTROPE, INC. | Directeur Général | 16/07/2014 |
| SYNAPTOGENIX, INC. | Directeur Général | 16/07/2014 |
| VELOXIS PHARMACEUTICALS A/S | Directeur Général | 01/01/2009 |
Abrika Pharmaceuticals LLP
 Abrika Pharmaceuticals LLP Pharmaceuticals: MajorHealth Technology Abrika Pharmaceuticals, Inc. develops and manufactures generic pharmaceuticals. The firm engages in the formulation and commercialization of both controlled release and immediate release products. The company was founded by Alan Phillip Cohen in May 2002 and is headquartered in Sunrise, FL. | Directeur Général | 01/01/2007 |
| NOVARTIS AG | Corporate Officer/Principal | - |
Formation de James New
| University of Maine | Graduate Degree |
| State University of New York College at Geneseo | Undergraduate Degree |
| State University of New York at Buffalo | Doctorate Degree |
| Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| NOVARTIS AG | Health Technology |
| PFIZER, INC. | Health Technology |
| GSK PLC | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| SYNAPTOGENIX, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Abrika Pharmaceuticals LLP
Abrika Pharmaceuticals LLP Pharmaceuticals: MajorHealth Technology Abrika Pharmaceuticals, Inc. develops and manufactures generic pharmaceuticals. The firm engages in the formulation and commercialization of both controlled release and immediate release products. The company was founded by Alan Phillip Cohen in May 2002 and is headquartered in Sunrise, FL. | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company, which engages in the development and commercialization of medicine for the prevention of organ rejection in kidney transplant patients. The company is focused on the direct commercialization of Envarsus XR in the US, expansion of partnerships for markets, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis Pharmaceuticals was founded in June 2002 and is headquartered in Copenhagen, Denmark. | Health Technology |
AIKO Biotechnology, Inc.
 AIKO Biotechnology, Inc. Miscellaneous Commercial ServicesCommercial Services AIKO Biotechnology, Inc. provides commercial physical research solutions and services. It offers treatment for pain and the side effects associated with prescription pain reliever (opioid) use, such as opioid-induced bowel dysfunction, addiction, and abuse. The company was founded in 2006 and is headquartered in Portland, ME. | Commercial Services |
Neurotrope, Inc.
 Neurotrope, Inc. Pharmaceuticals: MajorHealth Technology Neurotrope, Inc. is a biopharmaceutical company, which engages in the pre-clinical and clinical development of its product candidates. The company focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company was founded on January 11, 2011 and is headquartered in New York, NY. | Health Technology |
Wavodyne Therapeutics, Inc.
Wavodyne Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Wavodyne Therapeutics, Inc. develops and commercializes novel small molecule therapeutics for the treatment of memory and cognitive disorders resulting from neuro-inflammatory processes. The firm also provides research and development services. The company was founded by Jim New and is headquartered in Rochester, NY. | Health Technology |
